Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Emergent BioSolutions Inc. Common Stock
(NY:
EBS
)
10.95
+0.14 (+1.30%)
Official Closing Price
Updated: 7:00 PM EST, Nov 25, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Emergent BioSolutions Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Tuesday's after hours session: top gainers and losers
↗
April 15, 2025
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.
Via
Chartmill
Emergent BioSolutions Announces Stock Repurchase Program
March 31, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Expert Outlook: Emergent BioSolutions Through The Eyes Of 5 Analysts
↗
March 21, 2025
Via
Benzinga
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
March 20, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Where Emergent BioSolutions Stands With Analysts
↗
March 04, 2025
Via
Benzinga
The Analyst Verdict: Emergent BioSolutions In The Eyes Of 4 Experts
↗
January 21, 2025
Via
Benzinga
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
March 20, 2025
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
March 19, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
March 18, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
March 13, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
March 12, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
March 10, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Stocks Drop As Trade War Escalates: What's Driving Markets Tuesday?
↗
March 04, 2025
U.S. stocks plunged Tuesday as President Donald Trump‘s tariffs on key trade partners came into effect, prompting retaliatory measures and intensifying global trade tensions.
Via
Benzinga
Topics
World Trade
Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 30%, But Retail Clings To Profit Swing
↗
March 04, 2025
For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.
Via
Stocktwits
Emergent BioSolutions (EBS) Q4 2024 Earnings Call Transcript
↗
March 04, 2025
EBS earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
Get insights into the top gainers and losers of Monday's after-hours session.
↗
March 03, 2025
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.
Via
Chartmill
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
March 03, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday?
↗
March 03, 2025
Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%,...
Via
Benzinga
Earnings Scheduled For March 3, 2025
↗
March 03, 2025
Via
Benzinga
Nvidia, Tesla Lead Tech Stock Rebound: What's Driving Markets Friday?
↗
February 28, 2025
Stocks recovered on Friday, with all three major indexes in the green, as the tech sector bounced back from Thursday's losses with NVIDIA Corp. (NASDAQ:NVDA) up 1.37% and Tesla, Inc. (NASDAQ:TSLA)
Via
Benzinga
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
February 18, 2025
Separately, Company leaders will attend and present at J.P. Morgan’s 2025 Leveraged Finance Conference on February 24, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
↗
February 12, 2025
Via
Benzinga
Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
February 07, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
January 16, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
January 14, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
January 13, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
January 08, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)
January 08, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Why Emergent BioSolutions Stock Blasted Higher Today
↗
December 30, 2024
Via
The Motley Fool
Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November
↗
December 30, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today